- Previous Close
0.0108 - Open
0.0121 - Bid --
- Ask --
- Day's Range
0.0104 - 0.0121 - 52 Week Range
0.0010 - 0.1750 - Volume
471,400 - Avg. Volume
337,975 - Market Cap (intraday)
368,495 - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8000 - Earnings Date Oct 22, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.
www.quantum-genomics.comRecent News: ALQGC.PA
View MorePerformance Overview: ALQGC.PA
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALQGC.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALQGC.PA
View MoreValuation Measures
Market Cap
368.49k
Enterprise Value
-7.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.61
Price/Book (mrq)
0.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.31%
Return on Equity (ttm)
-156.81%
Revenue (ttm)
19.8k
Net Income Avi to Common (ttm)
-3.17M
Diluted EPS (ttm)
-0.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.55M
Total Debt/Equity (mrq)
622.18%
Levered Free Cash Flow (ttm)
--